Latest publications

Exposure-response analysis of Raltitrexed assessing liver toxicity

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Br J Clin Pharmacol

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

AbstractMismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI) colorectal cancers (CRC) represent...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Int J Cancer

Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial

Background: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine...

Posted by : Dr. Sophie PAGET-BAILLY
Journal name : Trials

Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group

AbstractBackground: Synchronous prostate cancer (PC) and rectal cancer (RC) is a rare clinical situation. While...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Ann Surg Oncol

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posted by : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : Bull Cancer

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

AbstractBackground: Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

26 2020, May

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review

AbstractBackground: Patients with severe renal impairment or undergoing hemodialysis are usually excluded from...

Posted by :
Journal name : Semin Oncol

Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)

AbstractPatients and methods: A post hoc analysis of all pathologic reports from patients with stage III CC...

Posted by : Mme. Julie HENRIQUES, Mr. Antoine FALCOZ, Dr. Dewi VERNEREY
Journal name : J Clin Oncol

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : J Natl Cancer Inst

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

AbstractBackground: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the...

Posted by : Dr. Dewi VERNEREY
Journal name : BMC Cancer

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

AbstractPurpose: The aim of this study was to investigate the association between expression of insulin-like growth...

Posted by : Mme. Julie HENRIQUES
Journal name : Cell Oncol (Dordr)

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...

Posted by : , Dr. Dewi VERNEREY
Journal name : World J Gastrointest Oncol

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative

AbstractKeywords: Adjuvant; Chemotherapy; Colon cancer; Guidelines; Randomised controlled trials; Time-to-event...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Journal name : Eur J Cancer

01 2020, March

Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

AbstractBackground: Despite improvement in colorectal liver metastasis (CLM) treatment, survival after liver...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Surg Oncol

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posted by : Dr. Dewi VERNEREY
Journal name : Clin Colorectal Cancer

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]

AbstractIntroduction: Perioperative chemotherapy is the standard strategy for localized gastric cancers....

Posted by : Dr. Dewi VERNEREY
Journal name : Bull Cancer

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

AbstractBackground: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of...

Posted by : Dr. Dewi VERNEREY
Journal name : Ann Oncol .

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Oncologist

01 2020, February

Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia

AbstractBackground: The use of absorbable meshes during contaminated or infected incisional hernia (IH) repair is...

Posted by : Mme. Julie HENRIQUES
Journal name : J Gastrointest Surg

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

AbstractBackground: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib...

Posted by : Mme. Julie HENRIQUES
Journal name : Cancer Imaging